Drug Patents owned by Janssen Therap

1. Drug name - SIRTURO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7498343 JANSSEN THERAP Mycobacterial inhibitors
Dec, 2026

(4 years from now)

US8546428 JANSSEN THERAP Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
Mar, 2029

(6 years from now)

CN101547904A JANSSEN THERAP Fumarate Salt Of (Alpha S, Beta R)-6-Bromo-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol
Dec, 2015

(6 years ago)

CN1671667A JANSSEN THERAP Quinoline Derivatives And Their Use As Mycobacterial Inhibitors
Jul, 2023

(9 months from now)

CN101070304B JANSSEN THERAP Quinoline Derivatives And Their Use As Mycobacterial Inhibitors
Jul, 2023

(9 months from now)

CN1325475C JANSSEN THERAP Quinoline Derivatives And Their Use As Mycobacterial Inhibitors
Jul, 2023

(9 months from now)

CN101070304A JANSSEN THERAP Quinoline Derivant And Its Application Used As Mycobacterium Inhibitor
Jul, 2023

(9 months from now)

IN236811B JANSSEN THERAP A Novel Substituted Quinoline Compound
Jul, 2023

(9 months from now)

IN200500220P1 JANSSEN THERAP A Novel Substituted Quinoline Compound
Jul, 2023

(9 months from now)

EP2301544B1 JANSSEN THERAP Quinoline Derivatives As Intermediates To Mycobacterial Inhibitors
Jul, 2023

(9 months from now)

EP2301544A1 JANSSEN THERAP Quinoline Derivatives As Intermediates To Mycobacterial Inhibitors
Jul, 2023

(9 months from now)

EP2086940A1 JANSSEN THERAP Fumarate Salt Of (Alpha S, Beta R)-6-Bromo-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol
Dec, 2027

(5 years from now)

EP2086940B1 JANSSEN THERAP Fumarate Salt Of (Alpha S, Beta R)-6-Bromo-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol
Dec, 2027

(5 years from now)

EP1527050B1 JANSSEN THERAP Quinoline Derivatives And Their Use As Mycobacterial Inhibitors
Jul, 2028

(5 years from now)

EP1527050A1 JANSSEN THERAP Quinoline Derivatives And Their Use As Mycobacterial Inhibitors
Jul, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.